Market News How it works Learn FAQ
| RCT 0.0827 8.67% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2427 9.57% | AZTR 1.53 113.99% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SHFS 0.094 -29.00% | SOXL 90.5 8.31% | INTC 90.47 4.04% | VALE 12 -3.23% | NVDA 216 2.39% | CLRO 4.97 52.92% | NOK 8.64 6.14% | JBLU 2.37 -9.71% | TSLL 10.76 10.25% | CRWV 55.19 1.76% | GCDT 0.1545 -12.27% | SOXS 47.98 -8.54% | RIG 6.53 1.87% | NWGL 0.0869 5.98% | ABEV 2.83 -14.24% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | RBNE 0.17 -10.53% | SID 0.9118 -22.73% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | LUCD 0.5007 21.82%
TLTiziana Life Sciences Ltd logo

Tiziana Life Sciences Ltd (TLSA)

NASDAQ Global Market · Currency in USD
$0.88 ▼ -0.07 (-7.14%)
At close: Oct 26, 4:00 PM ET. Market closed.
$0.88 ▲ +0.00 (+0.00%)
After hours: Oct 26, 4:38 PM ET

Summary

Previous Close
$0.95
Open
$0.94
Day's Range
$0.87 – $0.94
52 Week Range
$0.76 – $2.10
Volume
377,663
Avg. Volume
616,009
Market Cap
$112.28M
Beta (5Y Monthly)
0.44
PE Ratio (TTM)
--
EPS (TTM)
-$0.39
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Tiziana Life Sciences Ltd

Sector
Healthcare
Industry
Biotechnology
Full-time employees
10
CEO
Ivor R. Elrifi

Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression.

Earnings

DateEst.Actual
Oct 16, 2026-$0.08-$0.08Miss
May 1, 2026-$0.09-$0.22Miss
Oct 3, 2025-$0.07-$0.10Miss
Jul 8, 2025–-$0.06
Oct 18, 2024–-$0.18
May 10, 2024–-$0.18

Analyst view

Rating: Buy
Buy 75% · Hold 25% · Sell 0%

Get free alerts on TLSA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.